Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Other Non-Current Liabilities (2016 - 2025)

Editas Medicine (EDIT) has disclosed Other Non-Current Liabilities for 9 consecutive years, with $4.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Other Non-Current Liabilities rose 42.88% to $4.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $4.7 million, a 42.88% increase, with the full-year FY2024 number at $3.1 million, up 70.67% from a year prior.
  • Other Non-Current Liabilities was $4.7 million for Q3 2025 at Editas Medicine, up from $4.6 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $6.4 million in Q1 2025 to a low of $1.8 million in Q4 2023.
  • A 3-year average of $3.9 million and a median of $3.6 million in 2024 define the central range for Other Non-Current Liabilities.
  • Biggest YoY gain for Other Non-Current Liabilities was 83.21% in 2025; the steepest drop was 21.87% in 2025.
  • Editas Medicine's Other Non-Current Liabilities stood at $1.8 million in 2023, then skyrocketed by 70.67% to $3.1 million in 2024, then skyrocketed by 52.6% to $4.7 million in 2025.
  • Per Business Quant, the three most recent readings for EDIT's Other Non-Current Liabilities are $4.7 million (Q3 2025), $4.6 million (Q2 2025), and $6.4 million (Q1 2025).